脑膜转移癌的治疗管理和临床试验设计的挑战。
Management of leptomeningeal carcinomatosis and challenges of trial design.
机构信息
Icahn School of Medicine at Mount Sinai, New York, New York.
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Curr Opin Oncol. 2019 Nov;31(6):508-513. doi: 10.1097/CCO.0000000000000574.
PURPOSE OF REVIEW
Highlight recent data in lung and breast cancer leptomeningeal disease and address clinical trials that are open for patients.
RECENT FINDINGS
Patients with lung and breast cancer leptomeningeal disease have survival outcomes of less than 1 year, despite advances in treatment strategy. Efforts to develop liquid biopsy biomarkers of disease progression from cerebrospinal fluid and plasma are underway. There are over 10 clinical trials open for patients with leptomeningeal disease, half of which use immunotherapy.
SUMMARY
Consortium-based, multicenter clinical trials for patients with leptomeningeal disease are urgently needed to expand the treatment armamentarium.
目的综述
强调肺癌和乳腺癌脑膜疾病的最新数据，并介绍对患者开放的临床试验。
最新发现
尽管治疗策略有所进步，但肺癌和乳腺癌脑膜疾病患者的生存结果仍不到 1 年。目前正在努力从脑脊液和血浆中开发疾病进展的液体活检生物标志物。有超过 10 项针对脑膜疾病患者的临床试验正在进行，其中一半使用免疫疗法。
总结
迫切需要基于联合会的多中心临床试验来扩大脑膜疾病的治疗方法。
Zotero 插件